Cytokinetics (CYTK) Stock Price, News & Analysis

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings or view top-rated stocks.

15 analysts have issued 1-year target prices for Cytokinetics' shares. Their CYTK share price targets range from $50.00 to $108.00. On average, they expect the company's share price to reach $79.33 in the next year. This suggests a possible upside of 21.5% from the stock's current price.
View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts.

Cytokinetics' stock was trading at $83.49 on January 1st, 2024. Since then, CYTK shares have decreased by 21.8% and is now trading at $65.27.
View the best growth stocks for 2024 here.

Cytokinetics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 14,040,000 shares, an increase of 6.1% from the March 31st total of 13,230,000 shares. Based on an average daily volume of 2,030,000 shares, the short-interest ratio is presently 6.9 days. Currently, 13.9% of the shares of the company are sold short.
View Cytokinetics' Short Interest.

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) EPS for the quarter, missing analysts' consensus estimates of ($1.03) by $0.35. The biopharmaceutical company earned $1.70 million during the quarter, compared to the consensus estimate of $7.62 million. The business's quarterly revenue was down 10.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.45) EPS.

ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), Fidelity Disruptive Medicine ETF (FMED), Principal Healthcare Innovators ETF (BTEC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), VanEck Biotech ETF (BBH), BNY Mellon Innovators ETF (BKIV) and Harbor Health Care ETF (MEDI).

Cytokinetics updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million.

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Cytokinetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. (0.44%), Principal Financial Group Inc. (0.41%), Pinnacle Associates Ltd. (0.25%), Russell Investments Group Ltd. (0.23%), Swiss National Bank (0.17%) and BNP Paribas Financial Markets (0.16%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends.

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.